Does Monte Rosa Therapeutics (GLUE) Have the Potential to Rally 107.79% as Wall Street Analysts Expect?

Shares of Monte Rosa Therapeutics (GLUE) have gained 15.9% over the past four weeks to close the last trading session at $6.93, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $14.40 indicates a potential upside of 107.8%.The mean estimate comprises five short-term price targets with a standard deviation of $4.34. While the lowest estimate of $9 indicates a 29.9% increase from t ...